文献速递血脂与心血管预防冠心病

2型糖尿病合并心血管疾病患者的二级预防:TECOS试验国际洞察

Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
PubMed 文献 · Circulation · 2017-06-16

基线仅29.9%达到全部5项,71.8%达到至少4项;中位随访3.0年,达标评分越高结局越优,全达标vs≤2项调整HR 0.60(95%CI 0.47-0.77)。

要点

  • 糖尿病合并心血管病患者二级预防整体达标率低,仅29.9%达到全部5项。
  • 血压控制达标率最低(57.9%),不吸烟达标率最高(89%)。
  • 二级预防评分与心血管死亡、心梗或卒中呈阶梯式负相关。

核心结论

  • 国际试验人群中糖尿病合并心血管病患者的二级预防质量有显著改善空间,提高达标可降低下游心血管事件风险。

研究设计与样本

  • 采用逻辑回归评估基線二级预防达标的个体及区域因素,Cox比例风险回归分析达标与心血管死亡、心梗或卒中的关联。

主要发现

  • 基线29.9%达到全部5项二级预防参数,71.8%达到至少4项。
  • 北美达标比例最高(41.2%),西欧、东欧和拉丁美洲约25%。
  • 血压控制达标率最低(57.9%),不吸烟达标率最高(89%)。
  • 中位随访3.0年,基线二级预防评分越高结局越优,呈阶梯式分级关系;全达标vs≤2项调整HR 0.60(95%CI 0.47-0.77)。

关键数值与推荐

  • 5项二级预防参数:阿司匹林使用、血脂控制(LDL-C<70 mg/dL或他汀治疗)、血压控制(收缩压<140 mm Hg,舒张压<90 mm Hg)、ACEI或ARB使用、不吸烟状态。

临床怎么用

  • 临床应系统评估糖尿病合并心血管病患者的5项二级预防参数达标情况。
  • 重点关注血压控制,因其达标率最低。
  • 提高二级预防综合达标评分可能改善心血管结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intensive risk factor modification significantly improves outcomes for patients with diabetes mellitus and cardiovascular disease. However, the degree to which secondary prevention treatment goals are achieved in international clinical practice is unknown. METHODS: Attainment of 5 secondary prevention parameters-aspirin use, lipid control (low-density lipoprotein cholesterol <70 mg/dL or statin therapy), blood pressure control (<140 mm Hg systolic, <90 mm Hg diastolic), angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, and nonsmoking status-was evaluated among 13 616 patients from 38 countries with diabetes mellitus and known cardiovascular disease at entry into TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). Logistic regression was used to evaluate the association between individual and regional factors and secondary prevention achievement at baseline. Cox proportional hazards regression analysis was used to determine the association between baseline secondary prevention achievement and cardiovascular death, myocardial infarction, or stroke. RESULTS: Overall, 29.9% of patients with diabetes mellitus and cardiovascular disease achieved all 5 secondary prevention parameters at baseline, although 71.8% achieved at least 4 parameters. North America had the highest proportion (41.2%), whereas Western Europe, Eastern Europe, and Latin America had proportions of ≈25%. Individually, blood pressure control (57.9%) had the lowest overall attainment, whereas nonsmoking status had the highest (89%). Over a median 3.0 years of follow-up, a higher baseline secondary prevention score was associated with improved outcomes in a step-wise graded relationship (adjusted hazard ratio, 0.60; 95% confidence interval, 0.47-0.77 for those patients achieving all 5 measures versus those achieving ≤2). CONCLUSIONS: In an international trial population, significant opportunities exist to improve the quality of cardiovascular secondary prevention care among patients with diabetes mellitus and cardiovascular disease, which in turn could lead to reduced risk of downstream cardiovascular events. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00790205.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Pagidipati NJ, Navar AM, Pieper KS, et al. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). Circulation. 2017. PMID: 28626088. doi:10.1161/CIRCULATIONAHA.117.027252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。